Hypocalcaemia after denosumab in older people following fracture.
Hypocalcaemia following denosumab therapy can be observed in older adults. This is more common if their pre-treatment corrected serum calcium concentrations are less than 2.28 mmol/L. Denosumab remains a safe treatment in older people but we recommend a cautious approach in people at risk.



Previous studies have indicated that denosumab, an anti-RANK ligand (RANKL) monoclonal antibody, for treatment of osteoporosis is well-tolerated. There is little data specifically regarding its adverse effect profile in a hospitalised older person. Primarily, this study wished to determine the frequency of hypocalcaemia following denosumab administration in older people admitted to hospital following fracture. Secondarily, this study wished to determine any associations that may predict the development of hypocalcaemia.



This was a prospective study of 33 participants using a paired study design aged 70 years old or more with fragility fractures who were given denosumab in a rehabilitation hospital in Sydney. The primary outcome was the frequency of hypocalcaemia. Hypocalcaemia was defined as corrected serum concentration of less than 2.20 mmol/L on day 14 after denosumab administration.



Of the 33 participants with a mean age of 84.6 ± 1.2 years old, 5 participants (15.2 %) developed hypocalcaemia post injection. A paired t test showed a mean difference between the baseline and post injection calcium concentrations to be 0.059 mmol/L (95 %CI 0.020-0.098; t = 3.080, p = 0.004). Regression analysis showed that pre-denosumab serum calcium concentration correlated with the post-denosumab injection calcium concentration (R = 0.631, 95 %CI 0.288-0.977; p = 0.001). No other variables were significant. Further, a baseline serum calcium concentration of 2.28 mmol/L was able to predict post-denosumab hypocalcaemia with a sensitivity of 80 % and specificity of 86 %.



Denosumab is a relatively safe treatment of osteoporosis. This study shows that hypocalcaemia following denosumab therapy can be observed in older adults. Clinicians should be aware of this adverse effect when using denosumab in the older people.
Department of Aged Care, St George Hospital, Sydney, Australia. Weizhen.Chen@health.nsw.gov.au.
Jessica
http://orcid.org/0000-0003-1019-1966
J
Chen
Department of Aged Care, St George Hospital, Sydney, Australia.|School of Public Health and Community Medicine, University of NSW, Sydney, Australia.
Peter
P
Smerdely
D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002118:Calcium / Q000097:blood; D000069448:Denosumab / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D006996:Hypocalcemia / Q000097:blood / Q000139:chemically induced*; D007279:Injections, Subcutaneous; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control; D010865:Pilot Projects; D011446:Prospective Studies
D050071:Bone Density Conservation Agents; D000069448:Denosumab; D002118:Calcium
Denosumab; Hypocalcaemia; Older person; Osteoporosis; Safety profile
Br J Orthod. 1998 May;25(2):101-7
9668992
J Bone Miner Res. 2012 Jul;27(7):1471-9
22461041
Clin Ther. 2011 Nov;33(11):1547-59
22108301
Calcif Tissue Int. 2011 Aug;89(2):91-104
21637997
J Bone Miner Res. 2013 Nov;28(11):2317-24
23616397
J Gerontol. 1976 Sep;31(5):523-6
820738
J Bone Miner Res. 2006 Feb;21(2):324-31
16418789
Osteoporos Int. 2001;12(6):445-9
11446559
J Bone Miner Res. 2013 Apr;28(4):746-52
23109251
Case Rep Nephrol. 2014;2014:565393
25054070
Osteoporos Int. 1997;7 Suppl 3:S63-7
9536305
Arch Intern Med. 1986 Sep;146(9):1790-6
3530166
J Bone Miner Res. 2004 Jul;19(7):1059-66
15176987
Ter Arkh. 2014;86(10):60-4
25509894
Kidney Int. 2007 Jan;71(1):31-8
17091124
Bone. 1995 Apr;16(4 Suppl):301S-304S
7626318
N Engl J Med. 2009 Aug 20;361(8):756-65
19671655
JAMA. 2001 Feb 14;285(6):785-95
11176917
J Clin Endocrinol Metab. 1990 Aug;71(2):405-13
2380336
Am J Kidney Dis. 2012 Oct;60(4):626-8
22854051
Curr Med Res Opin. 2013 Sep;29(9):1067-73
23745518